BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Stemline Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Stemline Therapeutics\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05596409-9037@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elacestrant: Phase 2 readout est. (NCT05596409)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Rec
 eptor Positive\, HER-2 Negative Metastatic Breast Cancer Study\nEstimated 
 primary completion: November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/elacestrant#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05596409
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05563220-9037@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05563220)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elaces
 trant In Various Combination In Participants With Metastatic Breast Cancer
 \nEstimated primary completion: 27 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/elacestrant#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05563220
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05386108-9037@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Elacestrant: Phase 1/2 readout est. (NCT05386108)
DESCRIPTION:Elacestrant\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: Study of Abemaciclib and Elacestrant in Participants With Brain Met
 astasis Due to ER+/HER-2- Breast Cancer\nEstimated primary completion: Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elacestrant
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 86108
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456463-2839@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Tagraxofusp: Phase 2 readout est. (NCT06456463)
DESCRIPTION:Tagraxofusp\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study
  of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults W
 ith Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive C
 hemotherapy\nEstimated primary completion: 9 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tagraxofusp#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06456463
URL:https://assetmemo.bio/drug/tagraxofusp#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766018-9037@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Elacestrant: Phase 2 readout est. (NCT07766018)
DESCRIPTION:Elacestrant\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nSt
 udy: A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Me
 tastatic Breast Cancer\nEstimated primary completion: October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/elacestrant#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07766018
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492616-9037@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Elacestrant: Phase 3 readout est. (NCT06492616)
DESCRIPTION:Elacestrant\, phase 3\, Breast Cancer.\nStudy: A Study of Elace
 strant Versus Standard Endocrine Therapy in Women and Men With ER+\,HER2-\
 , Early Breast Cancer With High Risk of Recurrence\nEstimated primary comp
 letion: August 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 elacestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06492616
URL:https://assetmemo.bio/drug/elacestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
